While aiming to double its manufacturing capacity to more than 50 million blood tests per month, Siemens Healthineers has begun shipping its COVID-19 serology kits internationally, for use on about 20,000 analyzer systems installed worldwide.
The company recently received a CE mark for its IgM and IgG antibody test, designed to run on its high-throughput Advia Centaur and Atellica systems—the latter capable of running up to 440 tests per hour. The kit is currently being reviewed by the FDA for emergency use in the U.S.
Siemens plans to increase production at its sites in Walpole, Massachusetts, and Newark, Delaware, and said it expects to hit the 50-million test target in June.
The company also aims to ship more than 2.5 million molecular, PCR-based coronavirus tests each month, which received an FDA authorization early this month and a CE mark in late April. According to analysts at Bernstein, the company has already sold 500,000 tests in Europe.
Siemens described its total antibody test’s performance as 100% sensitivity and 99.8% specificity—including in detecting the neutralizing antibodies that connect to and block the novel coronavirus’s spike protein, which allows it to enter and infect cells.
“Not all antibody tests are created equal,” Siemens’ president of laboratory diagnostics, Deepak Nath, said in a statement. “A high-quality test that targets the right protein and is highly scalable is essential for antibody testing to help ensure we effectively manage the threat of COVID-19.”
“Siemens Healthineers sought to provide a highly accurate antibody test that could reach millions of people to address the current need for identifying immune response, and also for delivering long-term value as we look toward immunity and vaccination,” Nath added.
The company is also developing similar tests for its Dimension Vista and EXL systems, as well as a specific IgG test to meet different clinical needs.
By: Conor Hale
Source: Fierce Biotech
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.